Európai Unió - cseh - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotické činidla - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Európai Unió - cseh - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

sintetica gmbh, münster array - 1775 baklofen - infuzní roztok - 0,5mg/ml - baklofen

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

novartis s.r.o., praha array - 9564 monohydrÁt ciprofloxacin-hydrochloridu - ušní/oční kapky, roztok - 3mg/ml - ciprofloxacin

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

laboratoires thea, clermont-ferrand array - 1962 sodnÁ sŮl diklofenaku - oční kapky, roztok - 1mg/ml - diklofenak

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 3610 etoposid - koncentrát pro infuzní roztok - 20mg/ml - etoposid

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

ebewe pharma ges.m.b.h nfg.kg, unterach array - 3610 etoposid - koncentrát pro infuzní roztok - 20mg/ml - etoposid

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

teva pharmaceuticals cr, s.r.o., praha array - 3610 etoposid - koncentrát pro infuzní roztok - 20mg/ml - etoposid

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

pharmaand gmbh, vienna array - 2648 polykresulen; 354 cinchokain-hydrochlorid - Čípek - 100mg/2,5mg - cinchokain

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

pharmaand gmbh, vienna array - 2648 polykresulen; 354 cinchokain-hydrochlorid - rektální mast - 50mg/g+10mg/g - cinchokain